Department of Health and Social Care written question – answered on 7th September 2022.

Alert me about debates like this

Photo of Theresa Villiers Theresa Villiers Conservative, Chipping Barnet

To ask the Secretary of State for Health and Social Care, what discussions he has had with the NHS on making the drug Evusheld available for treatment of people with compromised immune systems who are at risk of serious harm from covid-19.

Photo of Maggie Throup Maggie Throup The Parliamentary Under-Secretary for Health and Social Care

The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is a decision based on independent clinical advice by the multi-agency initiative, RAPID C-19 and a national expert policy working group in the National Health Service. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies and concluded there is currently insufficient evidence of benefit to recommend deployment. The United Kingdom Chief Medical Officers are content that the correct process for providing clinical advice has been followed and agree that this should now be referred to the National Institute for Health and Care Excellence for further evaluation.

The Department wrote to patient groups on 5 September 2022 with information on this decision and evidence considered. The letter summarised the evidence considered by RAPID C-19 which contributed to the decision not to procure and deploy Evusheld and detailed the next steps the Government will take. The Department intends to publish further details of the clinical advice received shortly.

Does this answer the above question?

Yes0 people think so

No55 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.